In Situ Silver‐Based Electrochemical Oncolytic Bioreactor (Adv. Mater. 40/2022). Issue 40 (6th October 2022)

• Record Type: Journal Article
• Authors: Huang, Yong; Zhong, Liping; Li, Xiaotong; Wu, Pan; He, Jian; Tang, Chao; Tang, Zhiping; Su, Jing; Feng, Zhenbo; Wang, Bing; Ma, Yun; Peng, Hongmei; Bai, Zhihao; Zhong, Yi; Liang, Ying; Lu, Wenxi; Luo, Ruiyu; Li, Jinghua; Li, Haiping; Deng, Zhiming; Lan, Xianli; Liu, Ziqun; Zhang, Kun; Zhao, Yongxiang
• Is Part Of: Advanced materials. Volume 34:Issue 40(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-10-06
• Subjects: aptamer targeting -- intratumoral silver‐based nanosynthetic prodrugs -- primate biosafety -- silver‐based electrochemical oncolytic bioreactors -- 5, 5′, 6, 6′‐tetrachloro‐1, 1, 3, 3′‐tetraethylbenzimidazolyl carbocyanine iodide; Materials -- Periodicals; Chemical vapor deposition -- Periodicals; 620.11
• DOI: 10.1002/adma.202270280
• Languages: English
• ISSNs: 0935-9648

Abstract

Abstract : Bioreactors In article number 2109973, Liping Zhong, Kun Zhang, Yongxiang Zhao, and co‐workers describe how a tumor‐microenvironment‐enabled in situ silver‐based electrochemical oncolytic bioreactor (SEOB) unlocks antitumor Ag + prodrugs for highly efficient subcutaneous and orthotopic tumor recession via activating production of reactive oxygen species (ROS). Reduced graphene oxide (rGO), featuring 20‐fold larger catalysis rate than GO, allows intratumoral H2 O2 as reductants to reduce Ag + into silver nanoparticles especially after uniting with vitamin‐C‐mediated H2 O2 production.